Research Efforts Are Underway in the Prostate Cancer Paradigm

Christos Kyriakopoulos, MD, discusses key phase 1 results from the ongoing evaluation of masofaniten and enzalutamide in patients with mCRPC.

Christos Kyriakopoulos, MD, discusses data from a phase 1/2 study of masofaniten plus enzalutamide in metastatic castration-resistant prostate cancer.

Masofaniten administered in combination with enzalutamide (Xtandi) was tolerable, pharmacokinetically active, and led to a decrease in prostate-specific antigen levels at the recommended phase 2 dose in patients with metastatic castration-resistant prostate cancer.

Andrew Laccetti, MD, MS, discusses phase 1 findings from a phase 1/2 trial investigating masofaniten in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer.

Andrew Laccetti, MD, MS, discusses results from a phase 1 trial of masofaniten monotherapy in patients with metastatic castration-resistant prostate cancer and highlights the rationale for launching a phase 1/2 study evaluating masofaniten in combination with enzalutamide vs enzalutamide alone in this patient population.

The emergence of a novel class of compounds, known as anitens, potentially offers clinicians the ability to elongate responses for patients with metastatic castration-resistant prostate cancer, with the first-in-class N-terminal domain androgen receptor inhibitor masofaniten showing promise as it moves to the phase 2 portion of a phase 1/2 trial.